The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Chukanova E.I.

Pirogov Russian National Research Medical University (Pirogov University)

Chukanova A.S.

Pirogov Russian National Research Medical University (Pirogov University)

Brain aging: molecular targets of geroprotection and prevention strategies

Authors:

Chukanova E.I., Chukanova A.S.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(11): 132‑139

DOI: 10.17116/jnevro2025125111132

Read: 717 times

Buy for 300₽
Contact the author
Table of contents

BRAIN AGING: MOLECULAR TARGETS OF GEROPROTECTION AND PREVENTION STRATEGIES
BRAIN AGING: MOLECULAR TARGETS OF GEROPROTECTION AND PREVENTION STRATEGIES

To cite this article:

Chukanova EI, Chukanova AS. Brain aging: molecular targets of geroprotection and prevention strategies. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(11):132‑139. (In Russ.)
https://doi.org/10.17116/jnevro2025125111132

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Recommended articles:
Modern approaches to diagnosis and treatment of postinfectious asthenic syndrome in children. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):42-52
The main mechanisms of deve­lopment of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18
The known and new ideas about the mechanism of action and the spectrum of effe­cts of Mexi­dol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):22-33
Therapeutic pote­ntial of quercetin and its deri­vatives against COVID-19. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):44-50
Effect of uric acid on the progression of Parkinson’s disease: Myth or reality?. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):7-14
Resu­lts of the inte­rnational multicenter randomized, double-blind, placebo-controlled clinical trial for the evaluation of the effi­cacy and safety of the sequential therapy with ethy­lmethylhydroxypyridine succinate in patients in the acute and early reco­very periods of ischemic stroke (MIR). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):40-53
Morphological markers of mito­chondrial dysfunction of the basal plate cyto­trophoblast of the placenta in preeclampsia of varying seve­rity. Russian Journal of Archive of Pathology. 2025;(2):24-29
Rela­tionship between oxidative stress patterns and proinflammatory cyto­kines in patients with poly­pous rhinosinusitis under the course of therapeutic physical factors. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(2):42-49
Asso­ciations of gene­tic poly­morphisms in key inflammatory response genes with the risk of chro­nic apical periodontitis deve­lopment. Russian Journal of Stomatology. 2025;(2):52-56
The impact of Mexi­dol on improving quality of life para­meters and functional kidney status as part of complex therapy for cognitive impairments in como­rbid patients with microalbuminuria against the background of arte­rial hype­rtension and type 2 diabetes mellitus. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(4):478-478
Abstract:

The article provides an overview of domestic and foreign literature on the relevance of developing and implementing comprehensive medical and social methods for the prevention and treatment of gerontological pathologies. It examines the morphological and biochemical foundations of brain aging and presents methods for pharmacological correction of these changes. The use of the original domestic drug, the breadth of therapeutic effects of the drug ethylmethylhydroxypyridine succinate (Meksidol), based on its biochemical mechanisms of action, its high clinical efficacy, and the favorable safety profile of Meksidol in the absence of drug interactions, make its use promising in the comprehensive treatment of older patients.

Keywords:

brain aging
mitochondrial dysfunction
oxidative stress
cognitive functions
G-protein coupled receptor 91 protein
succinate
ethylmethylhydroxypyridine

Authors:

Chukanova E.I.

Pirogov Russian National Research Medical University (Pirogov University)

Chukanova A.S.

Pirogov Russian National Research Medical University (Pirogov University)

Received:

29.09.2025

Accepted:

30.09.2025

Close metadata

References:

  1. «Nacional’nye proekty» — informacionnyj resurs o planah razvitija strany na blizhajshee budushhee i merah po uluchsheniju kachestva zhizni ljudej. ANO «Nacional’nye prioritety», 2020—2025. (In Russ.). https://xn--80aapampemcchfmo7a3c9ehj.xn--p1ai/
  2. Gusev EI, Chukanova EI, Chukanova AS. Chronic Cerebrovascular Insufficiency (Risk Factors, Pathogenesis, Clinic, Treatment). M.: AST 345 LLC. 2018;203. UDC 616-089.98 LBC 51.1,23 Ch-88. (In Russ.).
  3. Salthouse TA. Consequences of age-related cognitive declines. Annual Rev Psychol. 2012;63:201-226.  https://doi.org/10.1146/annurev-psych-120710-100328
  4. Hedman AM, van Haren NE, Schnack HG, et al. Human brain changes across the life span: a review of 56 longitudinal magnetic resonance imaging studies. Hum Brain Map. 2012;33(8):1987-2002. https://doi.org/10.1002/hbm.21334
  5. Pfefferbaum A, Mathalon DH, Sullivan EV, et al. A quantitative magnetic resonance imaging study of changes in brain morphology from infancy to late adulthood. Arc Neurol. 1994;51(9):874-887.  https://doi.org/10.1001/archneur.1994.00540210046012
  6. Teissier T, Boulanger E, Deramecourt V. Normal ageing of the brain: Histological and biological aspects. Rev Neurol (Paris). 2020;176(9):649-660.  https://doi.org/10.1016/j.neurol.2020.03.017
  7. Moreno-García A, Kun A, Calero O, et al. An Overview of the Role of Lipofuscin in Age-Related Neurodegeneration. Front Neurosci. 2018;12:464.  https://doi.org/10.3389/fnins.2018.00464
  8. Dickstein DL, Weaver CM, Luebke JI, et al. Dendritic spine changes associated with normal aging. Neuroscience. 2013;251:21-32.  https://doi.org/10.1016/j.neuroscience.2012.09.077
  9. Huebner EA, Strittmatter SM. Axon regeneration in the peripheral and central nervous systems. Results Probl Cell Differ. 2009;48:339-351.  https://doi.org/10.1007/400_2009_19
  10. Suminaite D, Lyons DA, Livesey MR. Myelinated axon physiology and regulation of neural circuit function. Glia. 2019;67(11):2050-2062. https://doi.org/10.1002/glia.23665
  11. Peters A. The Effects of Normal Aging on Nerve Fibers and Neuroglia. In the Central Nervous System in Brain Aging: models, Methods, and Mechanisms. Ed. D.R. Riddle. CRC press: Boca Raton, (FL). 2007.
  12. Pannese E. Morphological changes in nerve cells during normal aging. Brain Struct. Funct Neurol. 2011;216(2):85-89.  https://doi.org/10.1007/s00429-011-0308-y
  13. Payne S. Cerebral Autoregulation: Control of Blood Flow. In the Brain in SpringerBriefs in Bioengineering. 1st Edn. Cham: Springer International Publishing. 2016.
  14. Heinz A. Elastic fibers during aging and disease. Ageing Res Rev. 2021;66:101255. https://doi.org/10.1016/j.arr.2021.101255
  15. Zimmerman B, Rypma B, Gratton G, et al. Age-related changes in cerebrovascular health and their effects on neural function and cognition: A comprehensive review. Psychophysiology. 2021;58(7):e13796. https://doi.org/10.1111/psyp.13796
  16. Schaare HL, Kharabian Masouleh S, Beyer F, et al. Association of peripheral blood pressure with gray matter volume in 19- to 40-year-old adults. Neurology. 2019;92(8):e758-e773. https://doi.org/10.1212/WNL.0000000000006947
  17. Maillard P, Seshadri S, Beiser A, et al. Effects of systolic blood pressure on white-matter integrity in young adults in the Framingham Heart Study: a cross-sectional study. Lancet Neurol. 2012;11(12):1039-1047. https://doi.org/10.1016/S1474-4422(12)70241-7
  18. Mattson MP, Arumugam TV. Hallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States. Cell Metab. 2018;27(6):1176-1199. https://doi.org/10.1016/j.cmet.2018.05.011
  19. Cunnane SC, Trushina E, Morland C, et al. Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing. Nat Rev Drug Discov. 2020;19(9):609-633.  https://doi.org/10.1038/s41573-020-0072-x
  20. Ureshino RP, Rocha KK, Lopes GS, et al. Calcium signaling alterations, oxidative stress, and autophagy in aging. Antioxid Redox Signal. 2014;21(1):123-137.  https://doi.org/10.1089/ars.2013.5777
  21. Iadecola C. Mechanisms of cerebral Ischemic damage. In: Cerebral Ischemia. Walz W (ed.). New Jersey: Totowa, Humana Press. 1999;3:33. 
  22. Voronina TA, Litvinova SA, Gladysheva NA, et al. The known and new ideas about the mechanism of action and the spectrum of effects of Mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(5):22-33. (In Russ.). https://doi.org/10.17116/jnevro202512505122
  23. Wang Y, Chang CF, Morales M, et al. Bone morphogenetic protein-6 reduces ischemia-induced brain damage in rats. Stroke. 2001;32:2170-2178. https://doi.org/10.1161/hs0901.095650
  24. Gomazkov OA. Neurotrophic regulation and brain stem cells. M.: IKAR. 2006;330. (In Russ.).
  25. Gomazkov OA. Neurotrophic regulation and brain stem cells. M.: IKAR. 2011;178. (In Russ.).
  26. Deen PM, Robben JH. Succinate receptors in the kidney. J Am Soc Nephrol. 2011;22(8):1416-1422. https://doi.org/10.1681/ASN.2010050481
  27. Chukanova EI, Chukanova AS, Andrianov DD. Arterial hypertension — oxidative stress as a pathogenetic target for the treatment of chronic cerebrovascular insufficiency. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(1):84-90. (In Russ.). https://doi.org/10.17116/jnevro202512501184
  28. Robben JH, Fenton RA, Vargas SL, et al. Localization of the succinate receptor in the distal nephron and its signaling in polarized MDCK cells. Kidney Int. 2009;76(12):1258-1267. https://doi.org/10.1038/ki.2009.360
  29. Chen TT, Maevsky EI, Uchitel ML. Maintenance of homeostasis in the aging hypothalamus: the central and peripheral roles of succinate. Front Endocrinol. (Lausanne). 2015;6:7.  https://doi.org/10.3389/fendo.2015.00007
  30. Gahr M, Connemann BJ, Schönfeldt-Lecuona CJ, et al. Succinic semialdehyde dehydrogenase deficiency: an inheritable neurometabolic disease. Fortschr Neurol Psychiatr. 2013;81(3):154-161.  https://doi.org/10.1055/s-0032-1330544
  31. Okovity SV, Radko SV, Shustov EB. Succinate receptors (SUCNR1) as a promising target for pharmacotherapy. Clinical and Pharmacological Journal. 2015;49(9):4-7. (In Russ.). https://doi.org/10.30906/0023-1134-2015-49-9-3-7
  32. Ariza AC, Deen MPT, Robben JH. The succinate receptor as a novel therapeutic target for oxidative and metabolic stress-related conditions. Front Endocrinol. 2012;3:1-8.  https://doi.org/10.3389/fendo.2012.00022
  33. Hamel D, Sanchez M, Duhamel F, et al. G-Protein-coupled receptor 91 and succinate are key contributors in neonatal postcerebral hypoxia-ischemia recovery. Arterioscler Thromb Vasc Biol. 2014;34(2):285-293.  https://doi.org/10.1161/ATVBAHA.113.302131
  34. Uittenbogaard M, Chiaramello A. Mitochondrial biogenesis: a therapeutic target for neurodevelopmental disorders and neurodegenerative diseases. Curr Pharm Des. 2014;20(35):5574-5593. https://doi.org/10.2174/1381612820666140305224906
  35. Voronina TA. Geroprotective effects of ethylmethylhydroxypyridine succinate in an experimental study. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(4):81-87. (In Russ.). https://doi.org/10.17116/jnevro202012004181
  36. Voronina TA. Svobodnoradikal’naya i mitohondrial’naya teorii stareniya. Effekty reparata Meksidol kak geroprotektora i geriatricheskogo sredstva. The book: Antioxidants. From the molecule to medical practice. Eds. TA Voronina, MM Tanashyan, AI Fedin, EYu Solov’eva. M.: Media Sfera. 2024;172-189. (In Russ.).
  37. Kirova YuI, Shakova FM, Voronina TA. Issledovanie cerebral’nyh effektov preparata Meksidol, oposredovannyh receptorom sukcinata SUCNR1: stimulyaciya mitohondriogeneza i protivovospalitel’noj polyarizacii mikroglii. The book: Antioxidants. From the molecule to medical practice. Eds. TA Voronina, MM Tanashyan, AI Fedin, EYu Solov’eva. M.: Media Sfera. 2024;143-171. (In Russ.).
  38. Novikov VE, Levchenkova OS, Ivantsova EN. Possibilities of antihypoxant use for mitochondrial dysfunctions. Vestnik Smolenskoy Gosudarstvennoy Meditsinskoy Akademii. 2020;19(1):41-55. (In Russ.).
  39. Voronina TA. Mexidol: spectrum of pharmacological effects. S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(12):86-90. (In Russ.).
  40. Cuadrado A. Structural and functional characterization of Nrf2 degradation by glycogen synthase kinase 3/β-TrCP. Free Radic Biol Med. 2015;88:147-157.  https://doi.org/10.1016/j.freeradbiomed.2015.04.029
  41. Shchulkin AV. Modern ideas about the antihypoxic and antioxidant effects of Mexidol. S.S. Korsakov Journal of Neurology and Psychiatry. Special issue. 2018;118(12-2):87-93. (In Russ.). https://doi.org/10.17116/jnevro201811812287
  42. Shchulkin AV. Effect of mexidol on the development of the phenomenon of the neuronal excitotoxicity in vitro. S.S. Korsakov Journal of Neurology and Psychiatry. 2012;112(2):35-39. (In Russ.).
  43. Camandola S, Mattson MP. Brain metabolism in health, aging, and neurodegeneration. EMBO J. 2017;36:1474-1492. https://doi.org/10.15252/embj.201695810
  44. Fumagalli M, Lombardi M, Gressens P, et al. How to reprogram microglia toward beneficial functions. Glia. 2018;66:2531-2549. https://doi.org/10.1002/glia.23484
  45. Kirova YuI, Shakova FM, Germanova EL, et al. The effect of Mexidol on cerebral mitochondrialogenesis in young adults and during aging. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(1):62-69. (In Russ.). https://doi.org/10.17116/jnevro202012001162
  46. Kirova YI, Shakova FM, Voronina TA. Ethylmethylhydroxypyridine succinate induces anti-inflammatory polarization of microglia in the aging rat brain. Biological Membranes. 2022;39(1):44-53. (In Russ.). https://doi.org/10.31857/S0233475521060049
  47. Kirova YuI, Germanova EL. New aspects of the energy-tropic action of mexidol. Patologicheskaia Fiziologiia i Eksperimental`Naia Terapiia. 2018;62(4):36-40. (In Russ.). https://doi.org/10.25557/0031-2991.2018.04.36-40
  48. Shakova FM. Mekhanizmy disregulyacii vnutrikletochnyh nejroprotektivnyh system pri ishemicheskom povrezhdenii golovnogo mozga (eksperimental’noe issledovanie): avtoref. diss. ... kand. biol. nauk. M. 2022. (In Russ.).
  49. Lukyanova LD. Signal’nye Mekhanizmy Gipoksii. M.: RAN. 2019. (In Russ.).
  50. Shchulkin AV, Chernykh IV, Abalenikhina YuV, et al. The effect of Mexidol on the level of neurogenesis markers in acute cerebrovascular accident in the experiment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;125(2):107-112. (In Russ.). https://doi.org/10.17116/jnevro2025125021107
  51. Gromova OA, Torshin IYu, Stakhovskaya LV, et al. Experience in the use of Mexidol in neurological practice. S.S. Korsakov Journal of Neurology and Psychiatry. 2018;118(10):97-107. (In Russ.). https://doi.org/10.17116/jnevro201811810197
  52. Tolkacheva VV, Kazakhmedov ER, Kobalava ZD, et al. Effect of Mexidol on the quality of life and functional status of patients with chronic cerebral ischemia and chronic heart failure with reduced left ventricular ejection fraction. Russian Journal of Cardiology and Cardiovascular Surgery. 2021;14(1):80-89. (In Russ.). https://doi.org/10.17116/kardio20211401180
  53. Shchulkin AV, Kazakhmedov ER, Galochkin SA, et al. Effects of mexidol in patients with chronic brain ischemia and chronic heart failure (II—III functional class). Russian Journal of Cardiology and Cardiovascular Surgery. 2020;13(5):427-434. (In Russ.). https://doi.org/10.17116/kardio202013051427
  54. Chukanova EI, Chukanova AS. Efficacy and safety of the drug mexidol FORTE 250 as part of sequential therapy in patients with chronic ischemia of the brain. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9):39-45. (In Russ.). https://doi.org/10.17116/jnevro201911909139
  55. Antipenko EA, Shulyndin AV, Belyakov KM. Neurometabolic therapy of mild cognitive impairment in patients with chronic cerebral ischemia. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(3):42-51. (In Russ.). https://doi.org/10.17116/jnevro202412403142
  56. Fedin AI, Zaharov VV, Tanashyan MM, et al. Results of an international multicenter, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO). S.S. Korsakov Journal of Neurology and Psychiatry. 2021;121(11):7-16. (In Russ.). https://doi.org/10.17116/jnevro20211211117
  57. Zakharov VV, Tkacheva ON, Mkhitaryan EA, et al. The Effectiveness of Mexidol in Patients of Different Age Groups with Chronic Cerebral Ischemia and Cognitive Impairments (Results of a Subanalysis of the International Multicenter Randomized Double-Blind Placebo-Controlled Study MEMO). S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(11 vol. 2):1-8. (In Russ.). https://doi.org/10.17116/jnevro202212211273
  58. Zakharov VV, Ostroumova OD, Kochetkov AI, et al. International multicenter randomized double-blind placebo-controlled study assessing the efficacy and safety of sequential therapy with Mexidol and Mexidol FORTE 250 in patients with chronic brain ischemia (MEMO): subanalysis in patients with arterial hypertension. Russian Journal of Preventive Medicine. 2024;27(10):72-83. (In Russ.). https://doi.org/10.17116/profmed20242710172
  59. Martynov AI, Tanashyan MM, Malyavin AG, et al. Resolution of the expert council «Possibilities of neuroprotective therapy in patients with arterial hypertension and cognitive disorders». Russian Journal of Preventive Medicine. 2024;27(11):85-93. (In Russ.). https://doi.org/10.17116/profmed20242711185
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.